Sorrento Therapeutics Management
Management criteria checks 3/4
Sorrento Therapeutics' CEO is Henry Ji, appointed in Sep 2012, has a tenure of 11.33 years. total yearly compensation is $10.07M, comprised of 20.1% salary and 79.9% bonuses, including company stock and options. directly owns 0.84% of the company’s shares, worth $508.10K. The average tenure of the management team and the board of directors is 4 years and 8.9 years respectively.
Key information
Henry Ji
Chief executive officer
US$10.1m
Total compensation
| CEO salary percentage | 20.1% |
| CEO tenure | 11.3yrs |
| CEO ownership | 0.8% |
| Management average tenure | 4yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M
Sep 29Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial
Sep 15Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103
Aug 31Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC
Aug 23Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading
Aug 17Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?
Jul 22
Sorrento Therapeutics: The Enigma
Jul 15Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical
Jul 07Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues
Mar 15Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates
Oct 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$548m |
| Mar 31 2023 | n/a | n/a | -US$672m |
| Dec 31 2022 | US$10m | US$2m | -US$573m |
| Sep 30 2022 | n/a | n/a | -US$494m |
| Jun 30 2022 | n/a | n/a | -US$524m |
| Mar 31 2022 | n/a | n/a | -US$472m |
| Dec 31 2021 | US$20m | US$2m | -US$428m |
| Sep 30 2021 | n/a | n/a | -US$355m |
| Jun 30 2021 | n/a | n/a | -US$320m |
| Mar 31 2021 | n/a | n/a | -US$231m |
| Dec 31 2020 | US$158m | US$839k | -US$298m |
| Sep 30 2020 | n/a | n/a | -US$290m |
| Jun 30 2020 | n/a | n/a | -US$270m |
| Mar 31 2020 | n/a | n/a | -US$249m |
| Dec 31 2019 | US$8m | US$781k | -US$292m |
| Sep 30 2019 | n/a | n/a | -US$279m |
| Jun 30 2019 | n/a | n/a | -US$262m |
| Mar 31 2019 | n/a | n/a | -US$279m |
| Dec 31 2018 | US$5m | US$670k | -US$204m |
| Sep 30 2018 | n/a | n/a | -US$105m |
| Jun 30 2018 | n/a | n/a | -US$60m |
| Mar 31 2018 | n/a | n/a | -US$378k |
| Dec 31 2017 | US$2m | US$600k | US$9m |
Compensation vs Market: Henry's total compensation ($USD10.07M) is above average for companies of similar size in the US market ($USD650.40K).
Compensation vs Earnings: Henry's compensation has been consistent with company performance over the past year.
CEO
Henry Ji (59 yo)
11.3yrs
Tenure
US$10,069,893
Compensation
Dr. Henry H. Ji, Ph D., serves as Executive Chairman at Scilex Holding Company since September 22, 2023. He serves as Director at Aardvark Therapeutics, Inc. since 2022.Dr. Ji served as Executive Chairman...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 11.3yrs | US$10.07m | 0.84% $ 508.1k | |
| Senior Vice President of Corporate Communications & Lymphatic Drug Development BU | 2yrs | no data | no data | |
| SVP & Chief Medical Officer | 4yrs | US$557.04k | no data | |
| Senior Vice President of Neurotherapeutics BU | 4yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 4yrs | no data | no data | |
| Senior Vice President of Commercial Operations | 4yrs | no data | no data | |
| President of ACEA | 2yrs | no data | no data |
4.0yrs
Average Tenure
Experienced Management: SRNE.Q's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 18yrs | US$10.07m | 0.84% $ 508.1k | |
| Independent Director | 6.3yrs | US$181.33k | 0% $ 0 | |
| Director | 10.3yrs | US$868.23k | 0.021% $ 12.5k | |
| Chair of Scientific Advisory Board & Director | 11.8yrs | US$82.50k | 0% $ 0 | |
| Independent Director | 7.4yrs | US$150.00k | 0.00092% $ 555.2 | |
| Lead Independent Director | 6.3yrs | US$250.02k | 0.00039% $ 235.4 |
8.9yrs
Average Tenure
60yo
Average Age
Experienced Board: SRNE.Q's board of directors are considered experienced (8.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/04 11:47 |
| End of Day Share Price | 2024/01/03 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sorrento Therapeutics, Inc. is covered by 15 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| James Molloy | Alliance Global Partners |
| Difei Yang | Brean Capital |